Application of oncolytic virus in tumor therapy

被引:32
作者
Huang, Zhijian [1 ]
Guo, Hongen [2 ]
Lin, Lin [3 ]
Li, Shixiong [1 ]
Yang, Yong [4 ]
Han, Yuanyuan [5 ,8 ]
Huang, Weiwei [3 ,9 ]
Yang, Jialiang [6 ,7 ,10 ]
机构
[1] Fujian Med Univ, Fujian Canc Hosp, Dept Breast Surg Oncol, Clin Oncol Sch, Fuzhou, Peoples R China
[2] Dermatol Hosp Fuzhou, Dept Dermatol, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China
[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Liver Ctr, Boston, MA USA
[5] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Ctr Tree Shrew Germplasm Resources, Kunming, Peoples R China
[6] Geneis Beijing Co Ltd, Beijing, Peoples R China
[7] Changsha Med Univ, Acad Workstat, Changsha, Peoples R China
[8] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming, Peoples R China
[9] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou 350014, Peoples R China
[10] Geneis Beijing Co Ltd, Beijing 100102, Peoples R China
关键词
combined therapy; genetic engineering; immunotherapy; oncolytic virus; tumor treatment; NEWCASTLE-DISEASE VIRUS; IMMUNOGENIC CELL-DEATH; HUMAN ADENOVIRUS; INTERFERON-BETA; CANCER-THERAPY; T-CELLS; IMMUNOTHERAPY; EXPRESSION; GENE; CYTOKINES;
D O I
10.1002/jmv.28729
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Oncolytic viruses (OVs) can selectively kill tumor cells without affecting normal cells, as well as activate the innate and adaptive immune systems in patients. Thus, they have been considered as a promising measure for safe and effective cancer treatment. Recently, a few genetically engineered OVs have been developed to further improve the effect of tumor elimination by expressing specific immune regulatory factors and thus enhance the body's antitumor immunity. In addition, the combined therapies of OVs and other immunotherapies have been applied in clinical. Although there are many studies on this hot topic, a comprehensive review is missing on illustrating the mechanisms of tumor clearance by OVs and how to modify engineered OVs to further enhance their antitumor effects. In this study, we provided a review on the mechanisms of immune regulatory factors in OVs. In addition, we reviewed the combined therapies of OVs with other therapies including radiotherapy and CAR-T or TCR-T cell therapy. The review is useful in further generalize the usage of OV in cancer treatment.
引用
收藏
页数:12
相关论文
共 154 条
[61]   Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade [J].
Jung, Bo-Kyeong ;
Ko, Hae Young ;
Kang, Hyunji ;
Hong, JinWoo ;
Ahn, Hyo Min ;
Na, Youjin ;
Kim, Hyeongi ;
Kim, Jin Su ;
Yun, Chae-Ok .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[62]   Effect of γ34.5 Deletions on Oncolytic Herpes Simplex Virus Activity in Brain Tumors [J].
Kanai, Ryuichi ;
Zaupa, Cecile ;
Sgubin, Donatella ;
Antoszczyk, Slawomir J. ;
Martuza, Robert L. ;
Wakimoto, Hiroaki ;
Rabkin, Samuel D. .
JOURNAL OF VIROLOGY, 2012, 86 (08) :4420-4431
[63]   Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges [J].
Kang, Synat ;
Li, Yisheng ;
Qiao, Jingqiao ;
Meng, Xiangyu ;
He, Ziqian ;
Gao, Xuefeng ;
Yu, Li .
FRONTIERS IN ONCOLOGY, 2022, 12
[64]   Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis [J].
Kasala, Dayananda ;
Lee, Soo-Hwan ;
Hong, JinWoo ;
Oh, Eonju ;
Yoon, A-Rum ;
Yun, Chae-Ok .
BIOMATERIALS SCIENCE, 2022, 10 (15) :4293-4308
[65]   Two roads for oncolytic immunotherapy development [J].
Kaufman, Howard L. ;
Bommareddy, Praveen K. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[66]   Oncolytic viruses: a new class of immunotherapy drugs [J].
Kaufman, Howard L. ;
Kohlhapp, Frederick J. ;
Zloza, Andrew .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) :642-+
[67]   Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy [J].
Kelly, K. R. ;
Espitia, C. M. ;
Zhao, W. ;
Wu, K. ;
Visconte, V. ;
Anwer, F. ;
Calton, C. M. ;
Carew, J. S. ;
Nawrocki, S. T. .
LEUKEMIA, 2018, 32 (01) :230-233
[68]   Arming oncolytic reovirus with GM-CSF gene to enhance immunity [J].
Kemp, Vera ;
van den Wollenberg, Diana J. M. ;
Camps, Marcel G. M. ;
van Hall, Thorbald ;
Kinderman, Priscilla ;
Pronk-van Montfoort, Nadine ;
Hoeben, Rob C. .
CANCER GENE THERAPY, 2019, 26 (9-10) :268-281
[69]   Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF [J].
Kim, J. H. ;
Oh, J. Y. ;
Park, B. H. ;
Lee, D. E. ;
Kim, J. S. ;
Park, H. E. ;
Roh, M. S. ;
Je, J. E. ;
Yoon, J. H. ;
Thorne, S. H. ;
Kirn, D. ;
Hwang, T. H. .
MOLECULAR THERAPY, 2006, 14 (03) :361-370
[70]   Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus [J].
Kirn, David H. ;
Wang, Yaohe ;
Le Boeuf, Fabrice ;
Bell, John ;
Thorne, Steve H. .
PLOS MEDICINE, 2007, 4 (12) :2001-2012